NCCN Guidelines for Patients Mantle Cell Lymphoma

Total Page:16

File Type:pdf, Size:1020Kb

Load more

NCCN GUIDELINES FOR PATIENTS® 2021 Mantle Cell Lymphoma Presented with support from: Available online at NCCN.org/patients Ü Mantle Cell Lymphoma It's easy to get lost in the cancer world Let NCCN Guidelines for Patients® be your guide 9 Step-by-step guides to the cancer care options likely to have the best results 9 Based on treatment guidelines used by health care providers worldwide 9 Designed to help you discuss cancer treatment with your doctors NCCN Guidelines for Patients®: Mantle Cell Lymphoma, 2021 1 About National Comprehensive Cancer Network® NCCN Guidelines for Patients® are developed by the National Comprehensive Cancer Network® (NCCN®) NCCN Clinical Practice NCCN Guidelines NCCN Guidelines in Oncology for Patients (NCCN Guidelines®) 9 An alliance of leading 9 Developed by doctors from 9 Present information from the cancer centers across the NCCN cancer centers using NCCN Guidelines in an easy- United States devoted to the latest research and years to-learn format patient care, research, and of experience 9 For people with cancer and education 9 For providers of cancer care those who support them all over the world Cancer centers 9 Explain the cancer care that are part of NCCN: 9 Expert recommendations for options likely to have the NCCN.org/cancercenters cancer screening, diagnosis, best results and treatment Free online at Free online at NCCN.org/patientguidelines NCCN.org/guidelines and supported by funding from NCCN Foundation® These NCCN Guidelines for Patients are based on the NCCN Guidelines® for B-Cell Lymphomas Version 3.2021 – March 16, 2021. © 2021 National Comprehensive Cancer Network, Inc. All rights reserved. NCCN Foundation seeks to support the millions of patients and their families NCCN Guidelines for Patients and illustrations herein may not be reproduced in affected by a cancer diagnosis by funding and distributing NCCN Guidelines for any form for any purpose without the express written permission of NCCN. No Patients. NCCN Foundation is also committed to advancing cancer treatment one, including doctors or patients, may use the NCCN Guidelines for Patients for by funding the nation’s promising doctors at the center of innovation in cancer any commercial purpose and may not claim, represent, or imply that the NCCN research. For more details and the full library of patient and caregiver resources, Guidelines for Patients that have been modified in any manner are derived visit NCCN.org/patients. from, based on, related to, or arise out of the NCCN Guidelines for Patients. The NCCN Guidelines are a work in progress that may be redefined as often National Comprehensive Cancer Network (NCCN) / NCCN Foundation as new significant data become available. NCCN makes no warranties of any 3025 Chemical Road, Suite 100 kind whatsoever regarding its content, use, or application and disclaims any Plymouth Meeting, PA 19462 responsibility for its application or use in any way. 215.690.0300 NCCN Guidelines for Patients®: Mantle Cell Lymphoma, 2021 2 Supporters Endorsed by Be The Match The Leukemia & Lymphoma Society Our Patient Support Center provides The Leukemia & Lymphoma Society confidential, one-on-one support, counseling (LLS) is dedicated to developing better and educational resources. Our team is here outcomes for blood cancer patients and if you want to learn about treatment options, their families through research, education, ask questions, access financial grants, or support and advocacy and is happy to have talk with others. All of our programs and this comprehensive resource available to resources are free. Call 1 888-999-6743 or patients. lls.org/patientsupport email: [email protected]. Website: bethematch.org/one-on-one The National Bone Marrow Transplant Link (nbmtLINK) Blood & Marrow Transplant Providing emotional and psychosocial Information Network (BMT InfoNet) support to patients and their families BMT InfoNet provides information and throughout the bone marrow/stem cell support services to patients undergoing transplant journey is an important part of a bone marrow, stem cell or cord blood the National Bone Marrow Transplant Link’s transplant service. Our mission is to mission. Visit our website, nbmtlink.org for empower patients and their loved ones hundreds of virtual free resources including with reliable information and support about Podcasts, Lunch & Learns, Webinars, issues before, during and after transplant so Peer Support and books for sale. Call us that they may take an active, informed role toll free, 800-LINK-BMT or email us: info@ in managing their healthcare choices. Visit nbmtlink.org. The nbmtLINK is supportive us online at bmtinfonet.org, or contact us by of wonderful resources such as the NCCN email at [email protected] and by phone Guidelines for Patients. nbmtlink.org 847-433-3313. bmtinfonet.org To make a gift or learn more, please visit NCCNFoundation.org/donate or e-mail [email protected]. NCCN Guidelines for Patients®: Mantle Cell Lymphoma, 2021 3 NCCN Guidelines for Patients®: Mantle Cell Lymphoma, 2021 4 Mantle Cell Lymphoma Contents 6 MCL basics 11 Testing 21 Treatment options 29 Treatment for advanced MCL 37 Early MCL and slow MCL 40 Making treatment decisions 49 Words to know 52 NCCN Contributors 53 NCCN Cancer Centers 54 Index NCCN Guidelines for Patients®: Mantle Cell Lymphoma, 2021 5 1 MCL basics 7 What is mantle cell lymphoma? 9 How common is mantle cell 7 What is the lymph system? lymphoma? 8 What is a mantle cell? 10 Can mantle cell lymphoma be cured? 8 What causes mantle cell lymphoma? 10 Review 9 How is mantle cell lymphoma identified? NCCN Guidelines for Patients®: Mantle Cell Lymphoma, 2021 6 1 MCL basics What is mantle cell lymphoma? Mantle cell lymphoma is a rare but What is the lymph system? treatable cancer of blood cells in lymph nodes and the lymph system. It’s often a The lymph system is part of the immune fast-growing cancer, but new treatments (infection-fighting) system. The lymph system every year are giving people more hope transports fluids to the bloodstream and fights and more years to live. germs. It’s made up of lymph, lymph nodes, and other organs. Lymph is a fluid that contains germ-fighting What is mantle cell lymphoma? lymphocytes. Lymph nodes (sometimes called “glands”) are small, bean-shaped structures. Hundreds of lymph nodes are located Mantle cell lymphoma (MCL) is cancer that throughout your body. As lymph fluid travels occurs in certain white blood cells. These through the body, lymph nodes catch and filter white blood cells are called lymphocytes. They out foreign particles and harmful cells. Lymph protect the body from infection. An abnormal nodes are usually clustered in groups in your growth of these lymphocytes is called a neck, chest, armpits, groin, pelvis, and along lymphoma. A lymphoma commonly affects the your gut. The spleen, tonsils, and thymus are lymph system, but it can also affect other parts also part of the lymph system. of the body. Lymph nodes There are hundreds of small bean-shaped structures throughout the human body called lymph nodes. Groups of lymph nodes are clustered in your neck, chest, armpits, groin, pelvis, and along your gut. Lymph nodes catch and filter out foreign particles and harmful cells, including cancer cells. NCCN Guidelines for Patients®: Mantle Cell Lymphoma, 2021 7 1 MCL basics What is a mantle cell? When you get an infection, an army of lymphocytes fills up your lymph nodes to fight the germs. That’s why the lymph nodes in your neck feel swollen when you have a cold, flu, or sinus infection. What is a mantle cell? What is cancer? Inside the lymph node are little round clumps called follicles. These follicles contain mostly B cells, a type of lymphocyte that plays a Cancer is a disease where cells—the key role in the immune system. Surrounding building blocks of the body—grow out of the center of each follicle is a mantle zone. control. This can end up harming the body. Imagine that the center of the follicle is a planet, like Saturn. The mantle zone is like the There are many types of cells in the body, ring that surrounds the planet. Mantle cells are so there are many types of cancers. B cells that lie in this mantle zone. Cancer cells don’t behave like normal cells. Cancer cells develop genetic errors that cause them to make many more cancer What causes mantle cell cells. The cancer cells crowd out and lymphoma? overpower normal cells. Cancer cells avoid normal cell death. They Researchers aren’t sure what actually causes also can spread far through blood or lymph this type of lymphoma. Most people who to other areas of the body. They can replace are diagnosed with MCL have developed many normal cells and cause organs to an unusual trait. This unique trait leads to a stop working. change in the B lymphocytes in the mantle zone in the lymph system. This change Scientists have learned a great deal about produces a buildup of a protein called cyclin cancer. As a result, today’s treatments work D1. This protein stimulates these abnormal much better than treatments in the past. cells to grow out of control and become Also, many people with cancer have more lymphoma cells. than one treatment choice. The big question is: What causes this unusual trait to occur in some B lymphocytes? Researchers don’t have an answer to that yet, but they’re working on it. NCCN Guidelines for Patients®: Mantle Cell Lymphoma, 2021 8 1 MCL basics How is mantle cell lymphoma identified? How is mantle cell lymphoma It’s important to identify your specific type of identified? lymphoma to make sure you get the right care and treatment. MCL is often discovered when a person has painless, swollen lymph nodes in the neck, armpit, or groin.
Recommended publications
  • The Lymphoma and Multiple Myeloma Center

    The Lymphoma and Multiple Myeloma Center

    The Lymphoma and Multiple Myeloma Center What Sets Us Apart We provide multidisciplinary • Experienced, nationally and internationally recognized physicians dedicated exclusively to treating patients with lymphoid treatment for optimal survival or plasma cell malignancies and quality of life for patients • Cellular therapies such as Chimeric Antigen T-Cell (CAR T) therapy for relapsed/refractory disease with all types and stages of • Specialized diagnostic laboratories—flow cytometry, cytogenetics, and molecular diagnostic facilities—focusing on the latest testing lymphoma, chronic lymphocytic that identifies patients with high-risk lymphoid malignancies or plasma cell dyscrasias, which require more aggresive treatment leukemia, multiple myeloma and • Novel targeted therapies or intensified regimens based on the other plasma cell disorders. cancer’s genetic and molecular profile • Transplant & Cellular Therapy program ranked among the top 10% nationally in patient outcomes for allogeneic transplant • Clinical trials that offer tomorrow’s treatments today www.roswellpark.org/partners-in-practice Partners In Practice medical information for physicians by physicians We want to give every patient their very best chance for cure, and that means choosing Roswell Park Pathology—Taking the best and Diagnosis to a New Level “ optimal front-line Lymphoma and myeloma are a diverse and heterogeneous group of treatment.” malignancies. Lymphoid malignancy classification currently includes nearly 60 different variants, each with distinct pathophysiology, clinical behavior, response to treatment and prognosis. Our diagnostic approach in hematopathology includes the comprehensive examination of lymph node, bone marrow, blood and other extranodal and extramedullary tissue samples, and integrates clinical and diagnostic information, using a complex array of diagnostics from the following support laboratories: • Bone marrow laboratory — Francisco J.
  • Low-Grade Non-Hodgkin Lymphoma Book

    Low-Grade Non-Hodgkin Lymphoma Book

    Low-grade non-Hodgkin lymphoma Low-grade non-Hodgkin lymphoma Follicular lymphoma Mantle cell lymphoma Marginal zone lymphomas Lymphoplasmacytic lymphoma Waldenström’s macroglobulinaemia This book has been researched and written for you by Lymphoma Action, the only UK charity dedicated to people affected by lymphoma. We could not continue to support you, your clinical team and the wider lymphoma community, without the generous donations of our incredible supporters. As an organisation we do not receive any government or NHS funding and so every penny received is truly valued. To make a donation towards our work, please visit lymphoma-action.org.uk/Donate 2 Your lymphoma type and stage Your treatment Key contact Name: Role: Contact details: Job title/role Name and contact details GP Consultant haematologist/ oncologist Clinical nurse specialist or key worker Treatment centre 3 About this book Low-grade (or indolent) non-Hodgkin lymphoma is a type of blood cancer that develops from white blood cells called lymphocytes. It is a broad term that includes lots of different types of lymphoma. This book explains what low-grade non-Hodgkin lymphoma is and how it is diagnosed and treated. It includes tips on coping with treatment and dealing with day-to-day life. The book is split into chapters. You can dip in and out of it and read the sections that are relevant to you at any given time. Important and summary points are written in the chapter colour. Lists practical tips and chapter summaries. Gives space for questions and notes. Lists other resources you might find useful, some of which are online.
  • Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy

    Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy

    cancers Review Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy Miriam Marangon 1, Carlo Visco 2 , Anna Maria Barbui 3, Annalisa Chiappella 4, Alberto Fabbri 5, Simone Ferrero 6,7 , Sara Galimberti 8 , Stefano Luminari 9,10 , Gerardo Musuraca 11, Alessandro Re 12 , Vittorio Ruggero Zilioli 13 and Marco Ladetto 14,15,* 1 Department of Hematology, Azienda Sanitaria Universitaria Giuliano Isontina, 34129 Trieste, Italy; [email protected] 2 Section of Hematology, Department of Medicine, University of Verona, 37134 Verona, Italy; [email protected] 3 Hematology Unit, ASST Papa Giovanni XXIII, 24127 Bergamo, Italy; [email protected] 4 Division of Hematology, Fondazione IRCCS, Istituto Nazionale dei Tumori, 20133 Milan, Italy; [email protected] 5 Hematology Division, Department of Oncology, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, Italy; [email protected] 6 Hematology Division, Department of Molecular Biotechnologies and Health Sciences, Università di Torino, 10126 Torino, Italy; [email protected] 7 Hematology 1, AOU Città della Salute e della Scienza di Torino, 10126 Torino, Italy 8 Hematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy; [email protected] 9 Hematology Unit, Azienda Unità Sanitaria Locale IRCCS di Reggio Emilia, 42123 Modena, Italy; [email protected] 10 Surgical, Medical and Dental Department of Morphological Sciences Related
  • Mantle Cell Lymphoma (MCL)

    Mantle Cell Lymphoma (MCL)

    Mantle Cell Lymphoma (MCL) Page 1 of 9 Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women. PATHOLOGIC DIAGNOSIS INITIAL EVALUATION ESSENTIAL: ● Physical exam: attention to node-bearing areas, including Waldeyer's ring, ESSENTIAL: size of liver and spleen, and patient’s age ● Hematopathology review of all slides with at least one tumor paraffin block. ● Performance status (ECOG) Hematopathology confirmation of classic versus aggressive variant of MCL ● B symptoms (fever, drenching night sweats, unintentional weight loss) (blastoid/pleomorphic). Re-biopsy if consult material is non-diagnostic. ● CBC with differential, LDH, BUN, creatinine, albumin, AST, total bilirubin, 1 ● Adequate immunophenotype to confirm diagnosis alkaline phosphatase, serum calcium, uric acid ○ Paraffin panel: ● Screening for HIV 1 and 2, hepatitis B and C (HBcAb, HBaAg, HCVAb) - Pan B-cell marker (CD19, CD20, PAX5), CD3, CD5, CD10, and cyclin D1 ● Beta-2 microglobulin (B2M) - Ki-67 (proliferation rate) ● Chest x-ray, PA and lateral or ● Bone marrow bilateral biopsy with unilateral aspirate Induction ○ Flow cytometry immunophenotyping:
  • Divergent Clonal Evolution of a Common Precursor to Mantle Cell Lymphoma and Classic Hodgkin Lymphoma

    Divergent Clonal Evolution of a Common Precursor to Mantle Cell Lymphoma and Classic Hodgkin Lymphoma

    Downloaded from molecularcasestudies.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma Hammad Tashkandi1, Kseniya Petrova-Drus1, Connie Lee Batlevi2, Maria Arcila1, Mikhail Roshal1, Filiz Sen1, Jinjuan Yao1, Jeeyeon Baik1, Ashley Bilger2, Jessica Singh2, Stephanie de Frank2, Anita Kumar2, Ruth Aryeequaye1, Yanming Zhang1, Ahmet Dogan1, Wenbin Xiao1,* 1Department of Pathology, 2Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY *Correspondence: Wenbin Xiao, MD, PhD Department of Pathology Memorial Sloan Kettering Cancer Center 1275 York Avenue New York, NY 10065 [email protected] Running title: Clonally related mantle cell lymphoma and classic Hodgkin lymphoma Words: 1771 Figures: 2 Tables: 1 Reference: 14 Supplemental materials: Figure S1-S2, Table S1-S4 Downloaded from molecularcasestudies.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press Abstract: Clonal heterogeneity and evolution of mantle cell lymphoma (MCL) remain unclear despite the progress in our understanding of its biology. Here we report a 71 years old male patient with an aggressive MCL and depict the clonal evolution from initial diagnosis of typical MCL to relapsed blastoid MCL. During the course of disease, the patient was diagnosed with Classic Hodgkin lymphoma (CHL), and received CHL therapeutic regimen. Molecular analysis by next generation sequencing of both MCL and CHL demonstrated clonally related CHL with characteristic immunophenotype and PDL1/2 gains. Moreover, our data illustrate the clonal heterogeneity and acquisition of additional genetic aberrations including a rare fusion of SEC22B-NOTCH2 in the process of clonal evolution.
  • Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions

    Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions

    Journal of Clinical Medicine Review Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions David A Bond 1,*, Peter Martin 2 and Kami J Maddocks 1 1 Division of Hematology, The Ohio State University, Columbus, OH 43210, USA; [email protected] 2 Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY 11021, USA; [email protected] * Correspondence: [email protected] Abstract: The increasing number of approved therapies for relapsed mantle cell lymphoma (MCL) provides patients effective treatment options, with increasing complexity in prioritization and se- quencing of these therapies. Chemo-immunotherapy remains widely used as frontline MCL treatment with multiple targeted therapies available for relapsed disease. The Bruton’s tyrosine kinase in- hibitors (BTKi) ibrutinib, acalabrutinib, and zanubrutinib achieve objective responses in the majority of patients as single agent therapy for relapsed MCL, but differ with regard to toxicity profile and dosing schedule. Lenalidomide and bortezomib are likewise approved for relapsed MCL and are active as monotherapy or in combination with other agents. Venetoclax has been used off-label for the treatment of relapsed and refractory MCL, however data are lacking regarding the efficacy of this approach particularly following BTKi treatment. Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies have emerged as highly effective therapy for relapsed MCL, with the CAR-T treatment brexucabtagene autoleucel now approved for relapsed MCL. In this review the authors summarize evidence to date for currently approved MCL treatments for relapsed disease including Citation: Bond, D.A; Martin, P.; sequencing of therapies, and discuss future directions including combination treatment strategies Maddocks, K.J Relapsed Mantle Cell and new therapies under investigation.
  • Mantle Cell Lymphoma

    Mantle Cell Lymphoma

    Leukemia (1998) 12, 1281–1287 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 http://www.stockton-press.co.uk/leu Mantle cell lymphoma: a retrospective study of 121 cases H Samaha1, C Dumontet1, N Ketterer1, I Moullet1, C Thieblemont1, F Bouafia1, E Callet-Bauchu2, P Felman2, F Berger3, G Salles1 and B Coiffier1 1Service d’He´matologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, and UPRES-JE 1879 ‘He´mopathies Lymphoides malignes’, Universite´ Claude Bernard, Pierre-Be´nite; 2Laboratoire d’He´matologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Be´nite; and 3Laboratoire d’Anatomie Pathologique, Hoˆpital Edouard-Herriot, Hospices Civils de Lyon, France Mantle cell lymphoma (MCL) patients represent a difficult prob- phoma usually begins as a disseminated disease with wide- lem, sometimes to establish the diagnosis but mostly because spread involvement of lymph nodes, spleen, bone marrow of their refractoriness to standard lymphoma treatments. Which treatments to apply and to whom is not yet defined. In this and other extranodal sites, specially the gastrointestinal tract study, we attempted to analyze the clinical features, to identify and Waldeyer ring. However, patients usually present a good the major prognostic factors, and to evaluate the outcome of performance status (PS) at diagnosis although adverse prog- 121 MCL patients treated in our institution between 1979 and nostic factors, such as high serum lactic dehydrogenase (LDH) 1997. Clinical data, treatment modalities, and International and ␤2-microglobulin levels, may be present. Initially, these Prognostic Index (IPI) score were evaluated. Median age was 63 patients usually respond to different types of therapy, but years.
  • Mantle Cell Lymphoma Presenting As Acute Abdominal Syndrome: a Rare Case Report and Literature Review

    Mantle Cell Lymphoma Presenting As Acute Abdominal Syndrome: a Rare Case Report and Literature Review

    healthcare Case Report Mantle Cell Lymphoma Presenting as Acute Abdominal Syndrome: A Rare Case Report and Literature Review Fu-Chou Lee 1, Junn-Liang Chang 2 , Hung-Ming Chen 3,4, Wan-Chen Tsai 5,6 and Po-Jen Hsiao 7,8,9,10,* 1 Department of Surgery, Taoyuan Armed Forces General Hospital, Taoyuan 325, Taiwan; [email protected] 2 Department of Pathology and Laboratory Medicine, Taoyuan Armed Forces General Hospital, Taoyuan 325, Taiwan; [email protected] 3 Division of Hematology and Oncology, Department of Internal Medicine, Taoyuan Armed Forces General Hospital, Taoyuan 325, Taiwan; [email protected] 4 Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan 5 Division of General Surgery, Department of Surgery, Taoyuan Armed Forces General Hospital, Taoyuan 325, Taiwan; [email protected] 6 Division of General Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan 7 Division of Nephrology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan 8 Division of Nephrology, Department of Internal Medicine, Taoyuan Armed Forces General Hospital, Taoyuan 325, Taiwan 9 Department of Life Sciences, National Central University, Taoyuan 325, Taiwan 10 Big Data Research Center, Fu-Jen Catholic University, New Taipei City 242, Taiwan * Correspondence: [email protected] or [email protected]; Tel.: +886-3-479-9595 Abstract: Background: Acute abdominal syndrome can be caused by several possible reasons. The Citation: Lee, F.-C.; Chang, J.-L.; most common causes are perforation of a gastroduodenal ulcer, peritonitis, intestinal obstructions, Chen, H.-M.; Tsai, W.-C.; Hsiao, P.-J.
  • The Cytogenetics of Hematologic Neoplasms 1 5

    The Cytogenetics of Hematologic Neoplasms 1 5

    The Cytogenetics of Hematologic Neoplasms 1 5 Aurelia Meloni-Ehrig that errors during cell division were the basis for neoplastic Introduction growth was most likely the determining factor that inspired early researchers to take a better look at the genetics of the The knowledge that cancer is a malignant form of uncon- cell itself. Thus, the need to have cell preparations good trolled growth has existed for over a century. Several biologi- enough to be able to understand the mechanism of cell cal, chemical, and physical agents have been implicated in division became of critical importance. cancer causation. However, the mechanisms responsible for About 50 years after Boveri’s chromosome theory, the this uninhibited proliferation, following the initial insult(s), fi rst manuscripts on the chromosome makeup in normal are still object of intense investigation. human cells and in genetic disorders started to appear, fol- The fi rst documented studies of cancer were performed lowed by those describing chromosome changes in neoplas- over a century ago on domestic animals. At that time, the tic cells. A milestone of this investigation occurred in 1960 lack of both theoretical and technological knowledge with the publication of the fi rst article by Nowell and impaired the formulations of conclusions about cancer, other Hungerford on the association of chronic myelogenous leu- than the visible presence of new growth, thus the term neo- kemia with a small size chromosome, known today as the plasm (from the Greek neo = new and plasma = growth). In Philadelphia (Ph) chromosome, to honor the city where it the early 1900s, the fundamental role of chromosomes in was discovered (see also Chap.
  • Mature B-Cell Neoplasms

    Mature B-Cell Neoplasms

    PEARLS OF LABORATORY MEDICINE Mature B-cell Neoplasms Michael Moravek, MD Kamran M. Mirza, MD, PhD Loyola University Chicago Stritch School of Medicine DOI: 10.15428/CCTC.2018.287706 © Clinical Chemistry The Lymphoid System Bone Marrow Stem Cell • Mature B-cell lymphomas comprise approximately 75% of all lymphoid neoplasms • Genetic alterations lead to deregulation of cell T cell Immature NK cell proliferation or apoptosis B cell • Low-grade lymphomas typically present as painless B cell lymphadenopathy, hepatosplenomegaly, or incidental lymphocytosis • High-grade lymphomas typically present with a rapidly enlarging mass and “B” symptoms (fever, weight loss, night sweats) Plasma cell 2 B-Cell Maturation antigen Naïve B cell Post- Germinal Center Germinal Center Marginal Zone DLBCL (some) FL, BL, some DLBCL, CLL/SLL Mantle Cell Hodgkin lymphoma MZL MALT Lymphoma Plasma cell myeloma CD5 + CD10 + CD5/CD10 Neg 3 Frequency among mature B-cell neoplasms DLBCL 27.6% CLL/SLL 19.4% Mature B-cell neoplasms Chronic lymphocytic leukemia/small lymphocytic lymphoma Primary cutaneous follicle center lymphoma Follicular Lymphoma -Monoclonal B-12.2%cell lymphocytosis Mantle cell lymphoma Marginal Zone LymphomaB-cell prolymphocytic 3.7% leukemia -Leukemic non-nodal mantle cell lymphoma Splenic marginal zone lymphoma -In situ mantle cell neoplasia Mantle Cell LymphomaHairy cell leukemia1.9% Diffuse large B-cell lymphoma (DLBCL), NOS Splenic B-cell lymphoma/leukemia, unclassifiable -Germinal center B-cell type Burkitt Lymphoma -Splenic diffuse1.3% red pulp
  • Burkitt Lymphoma

    Burkitt Lymphoma

    Board Review- Part 2B: Malignant HemePath 4/25/2018 Small Lymphocytic Lymphoma SLL: epidemiology SLL: 6.7% of non-Hodgkin lymphoma. Majority of patients >50 y/o (median 65). M:F ratio 2:1. Morphology • Lymph nodes – Effacement of architecture, pseudofollicular pattern of pale areas of large cells in a dark background of small cells. Occasionally is interfollicular. – The predominant cell is a small lymphocyte with clumped chromatin, round nucleus, ocassionally a nucleolus. – Mitotic activity usually very low. Morphology - Pseudofollicles or proliferation centers contain small, medium and large cells. - Prolymphocytes are medium-sized with dispersed chromatin and small nucleoli. - Paraimmunoblasts are medium to large cells with round to oval nuclei, dispersed chromatin, central eosinophilic nucleoli and slightly basophilic cytoplasm. Small Lymphocytic Lymphoma Pseudo-follicle Small Lymphocytic Lymphoma Prolymphocyte Paraimmunoblast Immunophenotype Express weak or dim surface IgM or IgM and IgD, CD5, CD19, CD20 (weak), CD22 (weak), CD79a, CD23, CD43, CD11c (weak). CD10-, cyclin D1-. FMC7 and CD79b negative or weak. Immunophenotype Cases with unmutated Ig variable region genes are reported to be CD38+ and ZAP70+. Immunophenotype Cytoplasmic Ig is detectable in about 5% of the cases. CD5 and CD23 are useful in distinguishing from MCL. Rarely CLL is CD23-. Rarely MCL is CD23+. Perform Cyclin D1 in CD5+/CD23- cases. Some cases with typical CLL morphology may have a different profile (CD5- or CD23-, FMC7+ or CD11c+, or strong sIg, or CD79b+). Genetics Antigen receptor genes: Ig heavy and light chain genes are rearranged. Suggestion of 2 distinct types of SLL defined by the mutational status of the IgVH genes: 40-50% show no somatic mutations of their variable region genes (naïve cells, unmutated).
  • PRESCRIBING INFORMATION ------CONTRAINDICATIONS ------These Highlights Do Not Include All the Information Needed to Use None

    PRESCRIBING INFORMATION ------CONTRAINDICATIONS ------These Highlights Do Not Include All the Information Needed to Use None

    HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------------ CONTRAINDICATIONS ------------------------------ These highlights do not include all the information needed to use None. (4) BRUKINSA safely and effectively. See full prescribing information for BRUKINSA. ----------------------- WARNINGS AND PRECAUTIONS ----------------------- • Hemorrhage: Monitor for bleeding and manage appropriately. (5.1) BRUKINSA® (zanubrutinib) capsules, for oral use • Infections: Monitor patients for signs and symptoms of infection, Initial U.S. Approval: 2019 including opportunistic infections, and treat as needed. (5.2) • Cytopenias: Monitor complete blood counts during treatment. (5.3) --------------------------- RECENT MAJOR CHANGES --------------------------- • Indications and Usage (1.2) 8/2021 Second Primary Malignancies: Other malignancies have occurred in Indications and Usage (1.3) 9/2021 patients including skin cancers. Advise patients to use sun protection. Dosage and Administration (2.1) 9/2021 (5.4) Warnings and Precautions (5) 9/2021 • Cardiac Arrhythmias: Monitor for atrial fibrillation and atrial flutter and manage appropriately. (5.5) --------------------------- INDICATIONS AND USAGE ---------------------------- • Embryo-Fetal Toxicity: Can cause fetal harm. Advise women of the BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients potential risk to a fetus and to avoid pregnancy. (5.6) with: • Mantle cell lymphoma (MCL) who have received at least one prior ------------------------------ ADVERSE REACTIONS